Ventyx Biosciences Stock Performance
| VTYX Stock | USD 2.44 0.21 7.92% |
Ventyx Biosciences holds a performance score of 12 on a scale of zero to a hundred. The entity has a beta of 1.32, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ventyx Biosciences will likely underperform. Use Ventyx Biosciences expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on Ventyx Biosciences.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ventyx Biosciences are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Ventyx Biosciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.92) | Five Day Return 9.42 | Year To Date Return 14.02 | Ten Year Return (88.39) | All Time Return (88.39) |
1 | Disposition of 96778 shares by Raju Mohan of Ventyx Biosciences at 0.2 subject to Rule 16b-3 | 03/18/2025 |
2 | Insiders US1.26m Investments In Red Following Ventyx Biosciences US11m Dip In Market Value | 03/31/2025 |
3 | Ventyx Biosciences chief scientific officer John Nuss sells 2,019 in shares - Investing.com | 04/03/2025 |
4 | Acquisition by Subramaniam Somu of 20000 shares of Ventyx Biosciences at 1.97 subject to Rule 16b-3 | 04/14/2025 |
5 | Press Release Distribution PR Platform - ACCESS Newswire | 04/22/2025 |
6 | Is Ventyx Biosciences In A Good Position To Deliver On Growth Plans | 05/05/2025 |
7 | Ventyx Advances NLRP3 Inhibitor Trials Targeting Multiple Diseases VTYX Stock News | 05/08/2025 |
8 | Disposition of 4312 shares by Raju Mohan of Ventyx Biosciences at 5.4034 subject to Rule 16b-3 | 05/09/2025 |
9 | Buy Rating for Ventyx Biosciences Promising Clinical Trials and Strong Financial Position - TipRanks | 05/13/2025 |
10 | Acquisition by Forman Mark S of 3000 shares of Ventyx Biosciences at 1.03 subject to Rule 16b-3 | 05/15/2025 |
11 | Spotlight On 3 Penny Stocks With Market Caps Under 500M | 05/21/2025 |
12 | Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference | 05/28/2025 |
13 | Ventyx Biosciences Holds Annual Stockholders Meeting - TipRanks | 06/10/2025 |
| Begin Period Cash Flow | 52.6 M |
Ventyx Biosciences Relative Risk vs. Return Landscape
If you would invest 141.00 in Ventyx Biosciences on March 14, 2025 and sell it today you would earn a total of 103.00 from holding Ventyx Biosciences or generate 73.05% return on investment over 90 days. Ventyx Biosciences is currently generating 1.1026% in daily expected returns and assumes 6.7196% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of stocks are less volatile than Ventyx, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ventyx Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ventyx Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ventyx Biosciences, and traders can use it to determine the average amount a Ventyx Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1641
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VTYX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.72 actual daily | 60 60% of assets are less volatile |
Expected Return
| 1.1 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Ventyx Biosciences is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ventyx Biosciences by adding it to a well-diversified portfolio.
Ventyx Biosciences Fundamentals Growth
Ventyx Stock prices reflect investors' perceptions of the future prospects and financial health of Ventyx Biosciences, and Ventyx Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ventyx Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (29.68 M) | ||||
| Shares Outstanding | 71.16 M | ||||
| Price To Book | 0.79 X | ||||
| EBITDA | (133.77 M) | ||||
| Net Income | (135.12 M) | ||||
| Cash And Equivalents | 250.45 M | ||||
| Cash Per Share | 4.92 X | ||||
| Total Debt | 10.79 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.27 X | ||||
| Book Value Per Share | 3.25 X | ||||
| Cash Flow From Operations | (130.87 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 188.58 M | ||||
| Total Asset | 276.56 M | ||||
| Retained Earnings | (554.31 M) | ||||
| Working Capital | 216.85 M | ||||
About Ventyx Biosciences Performance
Evaluating Ventyx Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Ventyx Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ventyx Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.56) | (0.53) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | (0.53) | (0.51) |
Things to note about Ventyx Biosciences performance evaluation
Checking the ongoing alerts about Ventyx Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ventyx Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ventyx Biosciences is way too risky over 90 days horizon | |
| Ventyx Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (135.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ventyx Biosciences currently holds about 250.45 M in cash with (130.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ventyx Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Ventyx Biosciences Holds Annual Stockholders Meeting - TipRanks |
- Analyzing Ventyx Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ventyx Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ventyx Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ventyx Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ventyx Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ventyx Biosciences' stock. These opinions can provide insight into Ventyx Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.